{"id":"start-antiplatelet-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antiplatelet monotherapy works by blocking one of the key pathways involved in platelet activation and aggregation, thereby reducing the risk of thrombotic events. This is typically achieved through inhibition of platelet function via mechanisms such as cyclooxygenase inhibition, P2Y12 receptor antagonism, or phosphodiesterase inhibition. The approach is used to prevent cardiovascular events in patients at risk of atherothrombotic disease.","oneSentence":"Antiplatelet monotherapy reduces blood clot formation by inhibiting platelet aggregation through a single antiplatelet agent.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:29.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary prevention of cardiovascular events"},{"name":"Acute coronary syndrome"},{"name":"Stroke prevention"}]},"trialDetails":[{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT04522102","phase":"PHASE3","title":"Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase","status":"COMPLETED","sponsor":"The George Institute for Global Health, China","startDate":"2021-09-03","conditions":"Intracerebral Hemorrhage","enrollment":80},{"nctId":"NCT04609111","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2021-01-29","conditions":"Acute Coronary Syndrome","enrollment":6002},{"nctId":"NCT05709626","phase":"PHASE4","title":"PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction","status":"RECRUITING","sponsor":"Kindai University","startDate":"2023-02-28","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":2258},{"nctId":"NCT01995370","phase":"PHASE4","title":"Cilostazol Stroke Prevention Study for Antiplatelet Combination","status":"COMPLETED","sponsor":"Japan Cardiovascular Research Foundation","startDate":"2013-12-13","conditions":"Noncardioembolic Cerebral Infarction","enrollment":1884},{"nctId":"NCT02756481","phase":"","title":"Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-10","conditions":"Non-Valvular Atrial Fibrillation","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Start antiplatelet monotherapy","genericName":"Start antiplatelet monotherapy","companyName":"The George Institute for Global Health, China","companyId":"the-george-institute-for-global-health-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiplatelet monotherapy reduces blood clot formation by inhibiting platelet aggregation through a single antiplatelet agent. Used for Secondary prevention of cardiovascular events, Acute coronary syndrome, Stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}